**Appendix Table E56. Results from studies assessing the ability of VASP to predict stroke in patients with ischemic heart disease**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author,year****UID****Country****Study name** | **Treatment** | **Phenotypic Test Used [index test]** | **Clinical Outcome** | **Outcome Definition** | **Timing of measurement** | **Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP** | **Outcome status (e.g., bleeding or no bleeding)** | **No. with outcome status within phenotype group** | **Comparative metric (OR, RR, HR)** | **95% CI** | **P (between which groups?)****[statistical test]** | **Adjusted?****[YES/NO/NR]****If YES, for what factors?** | **Procedures for multiple comparisons [YES, NO, NR]** | **Comments (e.g., additional data in figures)** |
| Schafer, 2011{Schafer, 2011 11 /id}21655677GermanyNR | Clopidogrel | VASP | ischaemic stroke | Ischemic stroke | 1 year | >57%(n=40) | Suboptima inhibition | 1 | OR(calculated)=1.1 | NR | P=0.953(>57% vs ≤ 57%)[Fisher’s exact] | NR | NR | NR |
|  |  |  |  |  |  | </=57%(n=14) |  | 0 | NR | NR | NR | NR | NR | NR |